ClinicalTrials.gg
CompletedNCT06813703Updated Aug 14, 2026

Analysis of the Analgesic Mechanism of TENS-WAA During Non-anesthetized Colonoscopy Using EEG-fNIRS System

An interventional study of Using an electrical stimulation device to relieve pain during colonoscopy in Colonoscopy and Pain, sponsored by First Affiliated Hospital of the Chinese People's Liberation Army Naval Medical University. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by First Affiliated Hospital of the Chinese People's Liberation Army Naval Medical University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 247 studies in Pain with a site in China — 66 open to participants now, 72 under way, 2 of them phase 3. Pain · China.

Enrollment
156th of 212
60 · median 120
Started
2025
with 34 others
No phase
117 of 247
40 open now
Registered
179th of 247
by date

Among the 247 studies in Pain with a site in China, this one is the 156th largest by enrollment of the 212 interventional ones that give a count, is one of 35 that started in 2025, is one of 117 with no phase, and was the 179th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

66 of the 247 studies in Pain with a site in China are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies in Pain with a site in China, or all of them as a file.
02

Study summary

This study is a single-center, randomized controlled trial aiming to evaluate the analgesic mechanism of Transcutaneous Electrical Nerve Stimulation based on Wrist-Ankle Acupuncture (TENS-WAA) during unsedated colonoscopy using EEG-fNIRS technology to assess neural activity in brain regions associated with pain perception. Sixty patients aged 18-75 years, with stable cardiopulmonary function and a baseline visual analog scale (VAS) pain score \<3, will be enrolled and randomly allocated into the intervention and control groups. The intervention group will receive TENS stimulation based on the Wrist-Ankle Acupuncture theory 10 minutes before the colonoscopy, with a frequency of 2 Hz and adjustable current intensity ranging from 1 to 9 mA. The control group will receive minimal-intensity sham stimulation under identical conditions. All participants will wear EEG-fNIRS devices to monitor neural activity in key pain-related brain areas, including the prefrontal cortex, anterior cingulate cortex, motor cortex, and parietal cortex. Primary outcomes include EEG-fNIRS data, while secondary outcomes are VAS scores at the four colonic bends, colonoscopy duration, and the correlation between EEG-fNIRS signals and pain perception. Statistical analyses will include multivariable linear regression, generalized estimating equations, and mixed-effects models to investigate the analgesic effects and neural mechanisms of TENS-WAA. This study seeks to provide innovative pain management strategies for patients undergoing unsedated colonoscopy and further explore the neuroregulatory potential of TENS-WAA technology.

03

Conditions studied

  • Colonoscopy
  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing unsedated colonoscopy are eligible for inclusion in this study.

    • Aged 18 to 75 years.
    • Meeting the requirements for colonoscopy, with good cardiopulmonary function and stable vital signs.
    • A pre-procedural Visual Analog Scale (VAS) pain score of less than 3.

Exclusion criteria

  • Participants with speech or cognitive impairments.

    • Those with acute anal or rectal stenosis, acute perianal or rectal infections, acute diverticulitis, or active inflammatory bowel disease.
    • Women who are menstruating, pregnant, or breastfeeding.
    • Patients with active tuberculosis, hemophilia, or advanced malignant tumors.
    • Individuals with sensory disturbances, implanted pacemakers or defibrillators, or ankle skin ulcers.
    • Those who have used sedatives or analgesics either long-term or within the past 24 hours.
    • Individuals with any condition that interferes with EEG-fNIRS signal acquisition, such as cranial abnormalities, implanted metal or electronic devices, epilepsy, or neurological disorders.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Electrical stimulation group

    According to the WAA theory, the selected Lower Zone 1 (LZ1) and Lower Zone 2 (LZ2) are defined as follows: LZ1 is located between the medial Achilles tendon and the medial malleolus, while LZ2 is positioned at the central inner edge of the ankle joint, near the posterior border of the tibia. Two electrode pads will be placed on each LZ1 and LZ2 of both legs, totaling eight electrode pads. The TENS-WAA device will be set to a frequency of 2 Hz, a pulse width of 500 μs, and a continuous waveform. Participants in the stimulation group will receive electrical currents at their maximum tolerable intensity below the pain threshold.

    Device: Using an electrical stimulation device to relieve pain during colonoscopy

  • Placebo comparator
    control group

    Participants in the control group will have the electrodes placed in the same positions as those in the stimulation group, with identical electrical stimulation frequency and pulse width settings. However, the current intensity will be set to the minimum level.

    Device: Using an electrical stimulation device to relieve pain during colonoscopy

Interventions

  • DeviceUsing an electrical stimulation device to relieve pain during colonoscopy

    In the electrical stimulation group, the device's current intensity will be adjusted to the maximum tolerance below the participant's pain threshold, while in the control group, the current intensity will be set to the minimum.

06

What researchers measure

Primary outcomes

  1. EEG-fNIRS Neurovascular Coupling Peak β Coefficient

    Neurovascular coupling is quantified from synchronized electroencephalography (EEG) and functional near-infrared spectroscopy (fNIRS) recordings. EEG activity is decomposed into predefined delta, theta, alpha, and beta frequency bands, and band-specific power envelopes are coupled with fNIRS-derived oxygenated haemoglobin (HbO) signals within predefined cortical regions of interest. A 10-second lag is applied to account for the delayed haemodynamic response following neural activity. Coupling is estimated using a general linear model. The peak β coefficient within the predefined analysis window is used to quantify maximum EEG-fNIRS neurovascular coupling strength. Values are calculated separately for the predefined frequency bands and cortical regions of interest and compared between the distal transcutaneous electrical nerve stimulation and sham stimulation groups.

    Time frame: During colonoscopy, at predefined procedural stages including anal intubation, splenic flexure, hepatic flexure, and cecal intubation, within the prespecified analysis window for each stage.

  2. EEG-fNIRS Neurovascular Coupling β Area Under the Curve

    Neurovascular coupling is quantified from synchronized electroencephalography (EEG) and functional near-infrared spectroscopy (fNIRS) recordings. EEG activity is decomposed into predefined delta, theta, alpha, and beta frequency bands, and band-specific power envelopes are coupled with fNIRS-derived oxygenated haemoglobin (HbO) signals within predefined cortical regions of interest. A 10-second lag is applied to account for the delayed haemodynamic response following neural activity. Coupling is estimated using a general linear model. The area under the β-coefficient curve (β AUC) within the predefined analysis window is used to quantify cumulative EEG-fNIRS neurovascular coupling strength over time. Values are calculated separately for the predefined frequency bands and cortical regions of interest and compared between the distal transcutaneous electrical nerve stimulation and sham stimulation groups.

    Time frame: During colonoscopy, at predefined procedural stages including anal intubation, splenic flexure, hepatic flexure, and cecal intubation, within the prespecified analysis window for each stage.

Secondary outcomes

  1. Pain VAS score

    Pain intensity is assessed using a 10-cm Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Participants report their pain intensity at three predefined procedural stages during colonoscopy: passage of the endoscope through the rectosigmoid junction, splenic flexure, and hepatic flexure.

    Time frame: During colonoscopy, when the endoscope passes through the rectosigmoid junction, splenic flexure, and hepatic flexure.

  2. EEG-Derived Cortical Neural Activity

    Cortical neural activity is assessed using electroencephalography (EEG) during predefined stages of colonoscopy. After signal preprocessing and artefact removal, EEG activity is analysed in four predefined frequency bands: delta, theta, alpha, and beta. Outcome measures include relative spectral power, reflecting frequency-specific cortical activity, and pairwise EEG coherence, reflecting functional synchronization between cortical regions. Stage-specific changes relative to the corresponding resting-state reference and between-group differences are evaluated to characterize alterations in cortical neural activity and network organization associated with procedural visceral pain and distal transcutaneous electrical nerve stimulation.

    Time frame: During colonoscopy at predefined procedural stages, including anal intubation, splenic flexure, hepatic flexure, and ileocecal valve.

  3. fNIRS-Derived HbO Cortical Activation

    Cortical activation is assessed using oxygenated haemoglobin (HbO) signals recorded by functional near-infrared spectroscopy (fNIRS). Event-related HbO responses are analysed using a general linear model within prespecified post-event time windows. Channel-wise β coefficients are estimated relative to position-matched resting-state recordings and are used to quantify the magnitude and direction of cortical HbO activation.

    Time frame: During colonoscopy, at predefined procedural stages including anal intubation, splenic flexure, hepatic flexure, and cecal intubation, within the prespecified post-event analysis window for each stage.

  4. fNIRS-Derived HbR Cortical Activation

    Cortical activation is assessed using deoxygenated haemoglobin (HbR) signals recorded by functional near-infrared spectroscopy (fNIRS). Event-related HbR responses are analysed using a general linear model within prespecified post-event time windows. Channel-wise β coefficients are estimated relative to position-matched resting-state recordings and are used to quantify the magnitude and direction of cortical HbR activation.

    Time frame: During colonoscopy, at predefined procedural stages including anal intubation, splenic flexure, hepatic flexure, and cecal intubation, within the prespecified post-event analysis window for each stage.

  5. fNIRS-Derived Cortical Functional Connectivity

    Cortical functional connectivity is assessed from fNIRS signals during predefined stages of colonoscopy. Functional connectivity between prespecified fNIRS channels or cortical regions is quantified using pairwise correlation coefficients to characterize stage-specific changes in cortical haemodynamic network organization. Connectivity measures are compared between the distal transcutaneous electrical nerve stimulation and control conditions.

    Time frame: During colonoscopy, at predefined procedural stages including anal intubation, splenic flexure, hepatic flexure, and cecal intubation.

  6. Colonoscopy time

    Time frame: during procedure (The total time to reach the three bends and to the ileocecal valve and for the entire examination was recorded)

07

Study locations

1 site
  • The First Affiliated Hospital of Naval Medical University
    Shanghai, Shanghai Municipality 200433, China
08

References and documents

Publications

  • Wang H, Huang X, Xu L, Guo S, Gong C, Mengcheng C, Wang W, Wang H, Fang F. Analysis of the analgesic mechanism of TENS-WAA in colonoscopy using the EEG-fNIRS system: a study protocol for a randomised controlled trial. BMJ Open. 2025 Sep 30;15(9):e103681. doi: 10.1136/bmjopen-2025-103681. PubMed 41033775 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) that will be shared include: Demographic information (age, sex, colonoscopy history) Group allocation (TENS-WAA or sham stimulation) Pain Visual Analogue Scale (VAS) scores at key time points EEG and fNIRS raw and pre-processed data collected before, during, and after colonoscopy Procedure duration and event timepoints (e.g., reaching hepatic flexure, splenic flexure, ileocecal valve) Relevant clinical outcomes (e.g., adverse events, procedure completion status) The data will be available from the corresponding author upon reasonable request, following publication of the main results and with a signed data access agreement. No data that could directly identify individual participants will be shared.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: The de-identified individual participant data (IPD) and supporting documents (such as data dictionaries and analysis code) will be available beginning 6 months after publication of the primary results article. Data will remain available for at least 5 years after publication, or longer if required by journal or institutional policy. Requests submitted after this period may be considered at the discretion of the corresponding author and study team.

Access criteria: Researchers from academic institutions, hospitals, or other recognized research organizations may access the de-identified individual participant data (IPD) and supporting documents (such as data dictionary and analysis code) for legitimate scientific research purposes by sending an email request to the corresponding author. The request should briefly describe the intended research use. All requests will be reviewed by the study team to ensure ethical compliance. Data sharing will require a signed data access agreement. Only de-identified data will be shared; no information that could directly identify participants will be provided.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Feb 2026, 11 months.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's 11 months is close to that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Feb 7, 2025
StartActual
Feb 18, 2025
Primary completionActual
Feb 1, 2026
CompletionActual
Mar 15, 2026
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06813703
Lead sponsor
First Affiliated Hospital of the Chinese People's Liberation Army Naval Medical University
Collaborators
Shanghai Shuli Intelligent Technology Co., Ltd
Responsible party
Xiaonan Huang (Clinical Professor, First Affiliated Hospital of the Chinese People's Liberation Army Naval Medical University) — Principal investigator
First posted
Feb 7, 2025
Start date
Feb 18, 2025
Primary completion
Feb 1, 2026
Completion
Mar 15, 2026
Last update
Aug 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion